> Myriad Genetics ($MYGN) has licensed its homologous recombination deficiency cancer test to its fifth partner in the space: oncology biotech Tesaro ($TSO). Story
> Biocept ($BIOC), a California developer of cancer molecular diagnostic tests, has hired a veteran of Life Technologies ($LIFE) and GE Healthcare's ($GE) Clarient as its new vice president of commercial operations. Release
> Minnesota's MGC Diagnostics ($MGCD) will acquire Belgium's Medisoft SA, a privately held maker of cardiorespiratory diagnostic products. Release
> The Alzheimer's Disease and Dementia Initiative at the New York Academy of Sciences and the Alzheimer's Drug Discovery Foundation, along with companies including AstraZeneca ($AZN), Merck ($MRK) and others, have funded an Australian trial that will attempt to validate a protein biomarker test to detect Alzheimer's disease. Story (reg. req.)
> More than 60 private labs in India have slashed the price on a key tuberculosis test in the run-up to World TB day. Story
> Editor's Note: A story in last week's FierceDiagnostics mischaracter